CVS Health vs. UnitedHealth: Comparing Revenue Trends for These Healthcare Companies

CVS Health and UnitedHealth both expanded revenue steadily through late 2025, then posted slight sequential declines in early 2026, raising the question of whether the pullback is temporary. In Q1 2026, CVS revenue rose to $100.4B with a 6% YoY increase, while UnitedHealth revenue reached $111.7B (+2% YoY). Both companies also raised full-year guidance, indicating expectations for a strong year ahead despite the early-2026 softness.

Analysis

The cleanest read here is not "who grew faster" but "who converts revenue into durable earnings power." UNH still screens as the higher-quality compounder because its margin structure makes each incremental dollar of revenue more accretive; CVS’s top line is more exposed to low-margin retail and pass-through volumes, so revenue stability by itself does not guarantee equity upside. The Omnicare divestiture is incrementally positive for CVS’s complexity and balance-sheet optionality, but it can also create a cosmetic revenue headwind that the market may punish more than the economic value warrants.

The bigger second-order issue is utilization control. UNH’s easing of prior authorization for rural providers reads like a customer-retention and political-risk management move, but it also opens the door to higher near-term service intensity if unit economics are not offset by pricing or mix improvements. CVS’s upside is more contingent on a true margin inflection than on raw sales, because pharmacy traffic and insurance scale can still mask weak operating leverage; if reimbursement or medical-cost pressure worsens, the revenue base won’t save the multiple.

Over the next 1-3 months, the catalyst is the next earnings print and any guidepost on medical loss ratio, pharmacy reimbursement, and same-store utilization. Over 6-18 months, the structural winner is likely the company that can defend spread margins while reducing friction with regulators and providers; that still favors UNH over CVS unless CVS proves that asset sales and mix shifts translate into higher ROIC. What would falsify this is simple: CVS needs margin expansion, not just revenue, while UNH would need a clear deterioration in medical cost trends or a guidance cut.

Consensus may be too relaxed about both names because the article frames revenue as the main variable. In healthcare, revenue quality matters more than revenue growth: pass-through and retail volume are worth less than control over medical cost ratio and administrative friction. That makes a relative-value long UNH / short CVS cleaner than an outright bullish call on either name.

Key Decisions for Investors

• Initiate a modest long UNH / short CVS pair trade over the next 1-3 months; target 8-12% relative outperformance if UNH holds margin and CVS fails to show margin expansion. Stop if CVS posts >100 bps margin improvement or UNH guidance is cut on medical-cost pressure.
• On CVS, avoid treating asset sales as a bullish operating signal; use any post-earnings pop to fade strength unless the company can show sustained gross-margin improvement and not just higher retail traffic. Best setup is a tactical short into strength ahead of the next quarterly update.
• Prefer buying UNH on pullbacks rather than chasing after a guide-up print; the key catalyst is confirmation that easing prior auth does not lift utilization faster than pricing. Reassess if medical-loss-ratio trends widen for two consecutive quarters.
• Watch for policy and reimbursement headlines in the next 30-90 days; a favorable CMS/rate environment would challenge the CVS short, while any regulatory noise around utilization control would be the main risk to UNH.